Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrografin for malignant bowel obstruction
ACTRN12610001029088Phase 2Not yet recruiting
- Sponsor
- Ian Bissett
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diatrizoate meglumine + diatrizoate sodium in malignant bowel obstruction (MBO), sponsored by Ian Bissett. Planned start Feb 2011; status: not yet recruiting.
02
Drugs
diatrizoate meglumine + diatrizoate sodium
03
Conditions
malignant bowel obstruction (MBO)
Beyond the preview
Go deeper on ACTRN12610001029088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610001029088.